HUTCHMED Begins Phase III for HMPL-760 HUTCHMED initiated a Phase III trial for HMPL-760 in China on Mar 23, 2026, advancing its lymphoma program to a pivotal stage and shifting valuation drivers to execution and differentiation.

HUTCHMED Begins Phase III for HMPL-760: HUTCHMED initiated a Phase III trial for HMPL-760 in China on Mar 23, 2026, advancing its lymphoma program to a pivotal stage and shifting valuation drivers to execution and… 👈 Read full analysis #HUTCHMED #PhaseIII #HMPL760 #LymphomaTreatment #Oncology